Inclusion Criteria:  Age 18 and above; Diagnosis of Gastrointestinal stromal tumor (GIST); At least 1 year post-initiation of TKI therapy; Report cognitive problems of memory and concentration attributed to GIST and/or treatment with a score of 10 or below on the FACT-Cog Impact on Quality of Life Scale; Able to speak and read English; Able to provide IRB-approved written informed consent; and Willingness to use videoconferencing and complete phone-based neurocognitive assessments  Exclusion Criteria:  Previous treatment with a tyrosine kinase inhibitor medication for a non-GIST diagnosis Previous CNS radiation, intrathecal therapy, or CNS-involved surgery; Previous cancer history with the exception of non-melanoma skin cancer; Previous exposure to chemotherapy with another cancer or due to other medical condition (e.g., methotrexate exposure for treatment of rheumatoid arthritis); Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;1 Significant neurodevelopmental, neurobehavioral, or medical risk factors likely to affect cognitive functioning (e.g., history of neurological disorder, stroke, traumatic brain injury greater than mild severity, such as loss of consciousness >30 minutes, medical disorder that is unstable or likely to affect cognition such as metabolic disorder, heart attack, uncontrolled diabetes or endocrine dysfunction); Current severe DSM-5 mental disorder criteria, including but not limited to neurodevelopmental, substance abuse, mood, anxiety, or psychotic disorders